Search - tctmd.com

Displaying 801 - 818 of 818

Sort: Relevancy | Date

News Industry News

Advanced Cardiac Therapeutics Announces CE Mark Clearance For Innovative Catheter System for the Treatment of Atrial Arrhythmias

June 10, 2011

News Daily News

Percutaneous Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Shows Low Mortality

L.A. McKeown

May 27, 2011

News Industry News

Medtronic’s Reveal® XT Insertable Cardiac Monitor Helps Determine AF Burden in Symptomatic and Asymptomatic Patients Following RF Ablation

May 05, 2011

News Industry News

Boston Scientific Announces CE Mark Approval and First Use of Blazer™ Open-Irrigated Catheter in Europe

May 03, 2011

News Industry News

Medtronic Announces FDA Clearance and First Patient Procedure with the Achieve™ Mapping Catheter

May 02, 2011

News Industry News

St. Jude Medical Receives FDA Approval for New Bi-Directional Ablation Catheters

April 04, 2011

News Conference News

PARTNER: TAVI Cost Effective Compared With Standard Care

Jason Kahn

April 03, 2011

News Industry News

Medtronic to Unveil Pivotal U.S. Data on Resolute® Drug-Eluting Stent at ACC.11

March 28, 2011

News Industry News

Advanced Cardiac Therapeutics Initiates First-In-Man CE Mark Clinical Trial to Study Innovative Catheter System for the Treatment of Atrial Arrhythmias

March 17, 2011

News Industry News

Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension

February 22, 2011

News Industry News

Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.

January 26, 2011

News Industry News

St. Jude Medical Announces Launch of the ViewMate Z Intracardiac Ultrasound System and ViewFlex Plus ICE Catheter

January 12, 2011

Partner Content

Hot Line Trials of the European Society of Cardiology 2024 Congress

August 22, 2024

Video

Concomitant AF Ablation-LAA Closure- Tilting the Scale Towards Open Surgery- - N. Doll

January 9, 2020

BIO

Byron K. Lee, MD

Video

» Interview

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

April 3, 2022

Video

» Interview

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

May 4, 2022

Advertisement

Advanced Cardiac Therapeutics Announces CE Mark Clearance For Innovative Catheter System for the Treatment of Atrial Arrhythmias

Percutaneous Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Shows Low Mortality

Medtronic’s Reveal® XT Insertable Cardiac Monitor Helps Determine AF Burden in Symptomatic and Asymptomatic Patients Following RF Ablation

Boston Scientific Announces CE Mark Approval and First Use of Blazer™ Open-Irrigated Catheter in Europe

Medtronic Announces FDA Clearance and First Patient Procedure with the Achieve™ Mapping Catheter

St. Jude Medical Receives FDA Approval for New Bi-Directional Ablation Catheters

PARTNER: TAVI Cost Effective Compared With Standard Care

Medtronic to Unveil Pivotal U.S. Data on Resolute® Drug-Eluting Stent at ACC.11

Advanced Cardiac Therapeutics Initiates First-In-Man CE Mark Clinical Trial to Study Innovative Catheter System for the Treatment of Atrial Arrhythmias

Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension

Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.

St. Jude Medical Announces Launch of the ViewMate Z Intracardiac Ultrasound System and ViewFlex Plus ICE Catheter

Hot Line Trials of the European Society of Cardiology 2024 Congress

Concomitant AF Ablation-LAA Closure- Tilting the Scale Towards Open Surgery- - N. Doll

Byron K. Lee, MD

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content